Articles related to COLORECTAL CANCER (CRC)

The ACP’s updated guidance on CRC screening highlights the significance of starting at age 50 and underscores the importance of shared decision-making in selecting appropriate screening methods.

A novel study has identified a distinct microbial fingerprint in patients with precancerous colon polyps, suggesting that the gut microbiome could play a pivotal role in early colorectal cancer detection.

Suflave™, an osmotic laxative approved by the FDA for colon cleansing in adults, represents a significant development in colonoscopy preparation. Patients interested in a low-volume option with improved taste attributes will find Suflave to be a promising alternative.

FOLFOX vs. Chemoradiotherapy: A Comparative Study in Locally Advanced Rectal Cancer Treatment A recent study has shed light on the efficacy of neoadjuvant FOLFOX (fluorouracil, leucovorin, and oxaliplatin) as an alternative to chemoradiotherapy in treating locally advanced rectal cancer. The findings suggest a potential shift in the standard care approach. “In patients with locally advanced rectal cancer who were eligible for sphincter-sparing surgery, preoperative FOLFOX was noninferior to preoperative chemoradiotherapy with respect to disease-free survival.” PROSPECT ClinicalTrials.gov number, NCT01515787

A 51-year-old man presents with a 10-week history of intermittent bright red blood per rectum. His medical history is unremarkable, and he takes no medications. Physical examination reveals normal vital signs and a normal digital rectal examination. Fecal occult blood is positive. A colonoscopy identifies a nonobstructing lesion located 10 cm from the anal verge, while the rest of the colon appears normal. MRI scan results indicate that the lesion is invading into the muscularis but has not breached the full thickness, and there are no abnormal lymph nodes detected. Additionally, a contrast-enhanced CT scan of the chest and abdomen shows no signs of metastases. Biopsy results confirm the presence of adenocarcinoma. What is the most appropriate treatment for this patient?

From November 15, 2015, to March 9, 2021, scientists conducted an open-label, phase 3 randomized clinical trial at 17 Spanish centers to assess the efficacy and safety of intraoperative HIPEC in patients with locally advanced colon cancer. The primary outcome was the 3-year locoregional control (LC) rate, which was defined as the proportion of patients who did not have peritoneal disease recurrence after adjusting for intention to treat. Patients included ranged in age from 18 to 75 years old and had been diagnosed with locally advanced primary colon cancer prior to surgery. They discovered that combining HIPEC with complete surgical resection for locally advanced colon cancer enhanced the 3-year LC rate compared to surgery alone, and they recommend that this strategy be evaluated for patients with locally advanced colorectal cancer.